1. Academic Validation
  2. METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma

METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma

  • Cell Commun Signal. 2023 May 25;21(1):121. doi: 10.1186/s12964-023-01148-7.
Bowen Liu # 1 Jinling Cao 2 Biting Wu 3 Kaixuan Hao 3 Xiangyun Wang 2 Xin Chen 2 Zhifa Shen # 4 5
Affiliations

Affiliations

  • 1 Laboratory of Infection and Immunology, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, 453003, People's Republic of China. [email protected].
  • 2 Laboratory of Infection and Immunology, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, 453003, People's Republic of China.
  • 3 Key Laboratory of Laboratory Medicine, Ministry of Education of China, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
  • 4 Laboratory of Infection and Immunology, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, 453003, People's Republic of China. [email protected].
  • 5 Key Laboratory of Laboratory Medicine, Ministry of Education of China, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, China. [email protected].
  • # Contributed equally.
Abstract

Background: It is well-established that most Hepatocellular carcinoma (HCC) patients die of metastasis, yet the potential mechanisms orchestrating metastasis remain poorly understood. Current evidence suggests that the dysregulation of METTL3-mediated m6A methylation modification is closely associated with Cancer progression. STAT3 is an oncogenic transcription factor that reportedly plays a central role in the occurrence and development of HCC. However, the relationship between METTL3 and STAT3 in HCC metastasis remains unclear.

Methods: The relationship between METTL3 expression and the survival of HCC patients was assessed by online tools GEPIA and Kaplan-Meier Plotter. Western blotting, Tissue microarray (TMA), and immunohistochemistry (IHC) staining were used to evaluate the expression levels of METTL3 and STAT3 in HCC cell lines and metastatic and non-metastatic tissues. Methylated RNA immunoprecipitation (MeRIP), MeRIP sequencing (MeRIP-seq), qRT-PCR, RNA immunoprecipitation (RIP), Western blotting and luciferase reporter gene assay were utilized to clarify the mechanism of METTL3 regulating STAT3 expression. Immunofluorescence staining, Western blotting, qRT-PCR, Co-immunoprecipitation (Co-IP), IHC staining, TMA and Chromatin immunoprecipitation (ChIP) assay were performed to explore the mechanism of STAT3 modulating METTL3 localization. Cell viability, wound healing and transwell assay, and orthotopic xenograft model were used to evaluate the role of METTL3-STAT3 feedback loop in the promotion of HCC metastasis in vitro and in vivo.

Results: METTL3 and STAT3 are both abundantly expressed in high-metastatic HCC cells and tissues. Moreover, a positive correlation was found between the expression of STAT3 and METTL3 in HCC tissues. Mechanistically, METTL3 could induce the m6A modification of STAT3 mRNA, and then promote the translation of m6A-contained STAT3 mRNA by interacting with the translation initiation machinery. In contrast, STAT3 promoted nuclear localization of METTL3 via transcriptionally upregulating WTAP, a vital member of the methyltransferase complex, and facilitated the methyltransferase function of METTL3. METTL3 and STAT3 form a positive feedback loop to accelerate HCC metastasis in vitro and in vivo.

Conclusions: Our findings reveal a novel mechanism of HCC metastasis and uncover the METTL3-STAT3 feedback signaling as a potential target for the anti-metastatic treatment of HCC. Video Abstract.

Keywords

Hepatocellular carcinoma; METTL3; Metastasis; STAT3; m6A methylation modification.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-134836
    99.87%, METTL3 Inhibitor